Cancer-associated thrombosis, low-molecular-weight heparin, and the patient experience: a qualitative study

References

• NobleSPasiJEpidemiology and pathophysiology of cancer-associated thrombosisBr J Cancer2010102Suppl 1S2S920386546
   PubMed Web of Science ®Google Scholar
• WhiteRHThe epidemiology of venous thromboembolismCirculation200310723 Suppl 1I-4I-812814979
   PubMed Web of Science ®Google Scholar
• KhoranaAAFrancisCWCulakovaEKudererNMLymanGHThromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapyJ Thromb Haemost20075363263417319909
   PubMed Web of Science ®Google Scholar
• BlomJWDoggenCJOsantoSRosendaalFRMalignancies, prothrombotic mutations, and the risk of venous thrombosisJAMA2005293671572215701913
   PubMed Web of Science ®Google Scholar
• PrandoniPLensingAWPiccioliARecurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosisBlood2002100103484348812393647
   PubMed Web of Science ®Google Scholar
• NobleSThe challenges of managing cancer related venous thromboembolism in the palliative care settingPostgrad Med J20078367167417989265
   PubMed Web of Science ®Google Scholar
• HuttenBAPrinsMHGentMGinsbergJTijssenJGBüllerHRIncidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysisJ Clin Oncol200018173078308310963635
   PubMed Web of Science ®Google Scholar
• BonaRDSivjeeKYHickeyADWallaceDMWajcsSBThe efficacy and safety of oral anticoagulation in patients with cancerThromb Haemost1995744105510588560413
   PubMed Web of Science ®Google Scholar
• KearonCAklEAComerotaAJAmerican College of Chest PhysiciansAntithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesChest2012141Suppl 2e419S494S22315268
   PubMed Web of Science ®Google Scholar
• FargeDDebourdeauPBeckersMInternational clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancerJ Thromb Haemost2013111567023217107
   PubMed Web of Science ®Google Scholar
• LymanGHKhoranaAAKudererNMAmerican Society of Clinical Oncology Clinical PracticeVenous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline updateJ Clin Oncol201331172189220423669224
   PubMed Web of Science ®Google Scholar
• LeeAYLevineMNBakerRIRandomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) InvestigatorsLow-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancerN Engl J Med2003349214615312853587
   PubMed Web of Science ®Google Scholar
• HullRDPineoGFBrantRFLITE Trial InvestigatorsLong-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancerAm J Med2006119121062107217145251
   PubMed Web of Science ®Google Scholar
• MeyerGMarjanovicZValckeJComparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled studyArch Intern Med2002162151729173512153376
   PubMed Web of Science ®Google Scholar
• DeitcherSRKesslerCMMerliGRigasJRLyonsRMFareedJONCENOX InvestigatorsSecondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day periodClin Appl Thromb Hemost200612438939617000884
   PubMed Web of Science ®Google Scholar
• NobleSIShelleyMDColesBWilliamsSMWilcockAJohnsonMJAssociation for Palliative Medicine for Great Britain and IrelandManagement of venous thromboembolism in patients with advanced cancer: a systematic review and meta-analysisLancet Oncol20089657758418510989
   PubMed Web of Science ®Google Scholar
• Soto-CárdenasMJPelayo-GarcíaGRodríguez-CamachoASegura-FernándezEMogollo-GalvánAGiron-GonzalezJAVenous thromboembolism in patients with advanced cancer under palliative care: additional risk factors, primary/secondary prophylaxis and complications observed under normal clinical practicePalliat Med200822896596818952751
   PubMed Web of Science ®Google Scholar
• NobleSIHoodKFinlayIGThe use of long-term low-molecular weight heparin for the treatment of venous thromboembolism in palliative care patients with advanced cancer: a case series of sixty two patientsPalliat Med200721647347617846086
   PubMed Web of Science ®Google Scholar
• AklEABarbaMRohillaSLow-molecular-weight heparins are superior to vitamin K antagonists for the long term treatment of venous thromboembolism in patients with cancer: a cochrane systematic reviewJ Exp Clin Cancer Res2008272118634550
   PubMed Web of Science ®Google Scholar
• NobleSIFinlayIGIs long-term low-molecular-weight heparin acceptable to palliative care patients in the treatment of cancer related venous thromboembolism? A qualitative studyPalliat Med200519319720115920933
   PubMed Web of Science ®Google Scholar
• KearonCKahnSRAgnelliGGoldhaberSRaskobGEComerotaAJAmerican College of Chest PhysiciansAntithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th ed)Chest2008133Suppl 6454S545S18574272
   PubMed Web of Science ®Google Scholar
• MacLeanSMullaSAklEAAmerican College of Chest PhysiciansPatient values and preferences in decision making for antithrombotic therapy: a systematic review: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesChest2012141Suppl 2e1Se23S22315262
   PubMed Web of Science ®Google Scholar
• SchulmanSKearonCKakkarAKRE-COVER Study GroupDabigatran versus warfarin in the treatment of acute venous thromboembolismN Engl J Med2009361242342235219966341
   PubMed Web of Science ®Google Scholar
• BauersachsRBerkowitzSDBrennerBEINSTEIN InvestigatorsOral rivaroxaban for symptomatic venous thromboembolismN Engl J Med2010363262499251021128814
   PubMed Web of Science ®Google Scholar
• BüllerHRPrinsMHLensinAWEINSTEIN–PE InvestigatorsOral rivaroxaban for the treatment of symptomatic pulmonary embolismN Engl J Med2012366141287129722449293
   PubMed Web of Science ®Google Scholar
• AgnelliGBullerHRCohenAPLIFY-EXT InvestigatorsApixaban for extended treatment of venous thromboembolismN Engl J Med2013368869970823216615
   PubMed Web of Science ®Google Scholar
• LiuGFranssenEFitchMIWarnerEPatient preferences for oral versus intravenous palliative chemotherapyJ Clin Oncol19971511101158996131
   PubMed Web of Science ®Google Scholar
• BornerMMSchoffskiPde WitRPatient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancerEur J Cancer200238334935811818199
   PubMed Web of Science ®Google Scholar
• FallowfieldLAtkinsLCattSPatients’ preference for administration of endocrine treatments by injection or tablets: results from a study of women with breast cancerAnn Oncol200617220521016239231
   PubMed Web of Science ®Google Scholar